Our Pricing

Understanding Mounjaro 7.5mg Equivalent To Wegovy: UK Dose Comparison

When considering mounjaro 7.5mg equivalent to wegovy, patients often ask which semaglutide dose delivers comparable weight loss results. Mounjaro 7.5mg (tirzepatide) represents the third maintenance dose in the titration schedule, whilst Wegovy's equivalent efficacy typically aligns with the 1.7mg to 2.4mg semaglutide range based on clinical trial data. Understanding this dose conversion helps UK patients and prescribers optimise treatment selection for sustainable weight management.

What Is The Mounjaro 7.5mg Equivalent To Wegovy Dose?

The mounjaro 7.5mg equivalent to wegovy question centres on comparing tirzepatide and semaglutide efficacy at specific doses. Clinical evidence from the SURPASS-2 head-to-head trial demonstrated that tirzepatide 10mg and 15mg produced superior weight loss compared to semaglutide 1mg, but no direct trial has compared Mounjaro 7.5mg against Wegovy's full dose range [1]. Based on weight reduction patterns observed across trials, Mounjaro 7.5mg typically achieves results comparable to Wegovy 1.7mg, though individual response varies significantly.

Tirzepatide's dual GIP/GLP-1 receptor mechanism distinguishes it from semaglutide's single GLP-1 action, making direct dose equivalence complex. In the SURMOUNT-1 trial, participants on tirzepatide 5mg (the dose before 7.5mg) achieved average weight loss of 15.0% over 72 weeks, whilst STEP trial data showed Wegovy 2.4mg delivered 14.9% average reduction [2]. This suggests Mounjaro 7.5mg likely sits between Wegovy 1.7mg and 2.4mg in terms of weight loss potential, subject to individual metabolic response and prescriber assessment.

How Mounjaro 7.5mg Equivalent To Wegovy Works In The Body

Understanding the mounjaro 7.5mg equivalent to wegovy requires examining how tirzepatide and semaglutide affect appetite regulation and glucose metabolism. Tirzepatide activates both GLP-1 and GIP receptors, enhancing insulin secretion, delaying gastric emptying, and reducing appetite through central nervous system pathways [3]. Wegovy's semaglutide acts solely on GLP-1 receptors but with high binding affinity and extended half-life, producing sustained appetite suppression over the weekly dosing interval.

At the 7.5mg dose, Mounjaro provides robust dual-receptor stimulation that many patients find produces earlier satiety and reduced food cravings compared to lower tirzepatide doses. Wegovy at equivalent weight-loss doses (1.7mg to 2.4mg) achieves similar appetite control through potent GLP-1 activation alone. Both medications require gradual dose escalation to minimise gastrointestinal side effects, with Mounjaro 7.5mg typically reached at week 12 of treatment following 2.5mg and 5mg starter doses.

Metabolic Differences Between Tirzepatide and Semaglutide

The mounjaro 7.5mg equivalent to wegovy comparison extends beyond weight loss to metabolic benefits. Tirzepatide's GIP receptor activation may enhance fat metabolism and improve lipid profiles more effectively than GLP-1 agonism alone, though both medications demonstrate cardiovascular benefits in clinical populations [4]. Patients with type 2 diabetes often see greater HbA1c reductions on tirzepatide compared to semaglutide at clinically equivalent doses, which influences prescriber choice when managing concurrent weight and glycaemic goals.

Clinical Evidence For Mounjaro 7.5mg Equivalent To Wegovy Efficacy

When evaluating mounjaro 7.5mg equivalent to wegovy outcomes, the SURPASS and STEP trial programmes provide the most robust evidence. SURPASS-2 directly compared tirzepatide doses (5mg, 10mg, 15mg) against semaglutide 1mg in adults with type 2 diabetes, showing dose-dependent weight reductions of 7.6kg, 9.3kg, and 11.2kg respectively versus 5.7kg for semaglutide 1mg over 40 weeks [1]. Whilst this trial used semaglutide 1mg rather than Wegovy's 2.4mg maximum, it establishes tirzepatide's superior efficacy trajectory.

The SURMOUNT-1 obesity trial evaluated tirzepatide in participants without diabetes, demonstrating 15.0%, 19.5%, and 20.9% mean body weight reductions at 5mg, 10mg, and 15mg doses over 72 weeks [2]. Wegovy's STEP 1 trial showed 14.9% average weight loss at 2.4mg over 68 weeks in a similar population. Extrapolating from these datasets, Mounjaro 7.5mg (positioned between the 5mg and 10mg trial doses) would theoretically produce weight loss in the 16-18% range, positioning it as clinically comparable to Wegovy 2.4mg for many patients, subject to individual response and prescriber assessment.

Real-World Outcomes at Mounjaro 7.5mg Dose

Beyond controlled trials, real-world evidence for mounjaro 7.5mg equivalent to wegovy outcomes is emerging from UK prescribing data. Many patients achieve significant weight loss at the 7.5mg maintenance dose without requiring escalation to 10mg or 15mg, particularly when combined with dietary modifications and increased physical activity. Clinical experience suggests approximately 60-70% of patients reach their target weight reduction goals at 7.5mg or lower tirzepatide doses, though this varies based on starting BMI, metabolic health, and adherence to lifestyle interventions alongside medication.

Side Effects: Mounjaro 7.5mg Equivalent To Wegovy Tolerability

Comparing mounjaro 7.5mg equivalent to wegovy side effect profiles helps patients set realistic expectations. Both medications share common GLP-1-mediated adverse effects including nausea, vomiting, diarrhoea, constipation, and abdominal discomfort, typically most pronounced during dose escalation phases [3]. Clinical trial data shows approximately 40-50% of participants on either tirzepatide or semaglutide experience mild-to-moderate gastrointestinal symptoms, with most resolving within 4-8 weeks as physiological adaptation occurs.

At the 7.5mg dose, Mounjaro's tolerability profile generally mirrors Wegovy 1.7mg to 2.4mg, with nausea rates around 30-35% and discontinuation due to adverse effects occurring in approximately 4-7% of users [2]. Tirzepatide's dual receptor mechanism does not appear to increase side effect burden compared to semaglutide monotherapy at weight-loss equivalent doses. Patients should report persistent vomiting, severe abdominal pain, or signs of pancreatitis (upper abdominal pain radiating to the back) to their prescriber immediately, as these require clinical assessment.

Mounjaro 7.5mg Equivalent To Wegovy: UK Pricing Comparison

When assessing mounjaro 7.5mg equivalent to wegovy cost in the UK, Mounjaro is available at Cured Pharmacy from £200.00 per four-week supply, subject to clinical assessment by a UK prescriber. This transparent upfront pricing includes the online consultation, prescription, and discreet next-day delivery across the UK. Wegovy pricing varies by dose, with starter packs and maintenance doses structured differently due to the medication's graduated titration schedule.

UK patients should consider total treatment cost over the full titration period when comparing mounjaro 7.5mg equivalent to wegovy value. Mounjaro requires 8-12 weeks to reach the 7.5mg maintenance dose (starting at 2.5mg, then 5mg), whilst Wegovy's escalation to 2.4mg typically spans 16-20 weeks through five dose increments. Cured Pharmacy offers £20 off first orders with code Weightlossnew, making initial treatment more accessible. Both medications require ongoing monthly prescriptions for sustained weight management, with clinical review recommended every 12 weeks to assess efficacy and tolerability.

Insurance and NHS Availability Considerations

The mounjaro 7.5mg equivalent to wegovy discussion in the UK includes NHS availability, which remains extremely limited due to NICE guidance restrictions and supply constraints. Most patients access these medications through private prescription services like Cured Pharmacy, where transparent pricing and rapid access avoid lengthy NHS waiting lists. Private treatment ensures continuity of supply and flexible prescriber consultations, though costs are entirely patient-funded. Some private medical insurance policies may cover GLP-1 medications for obesity when specific BMI and comorbidity criteria are met, subject to individual policy terms.

Choosing Between Mounjaro 7.5mg Equivalent To Wegovy Doses

Selecting the optimal mounjaro 7.5mg equivalent to wegovy dose requires individualised clinical assessment by a UK prescriber. Factors influencing choice include starting BMI, presence of type 2 diabetes, cardiovascular risk profile, previous weight loss medication history, and patient preference regarding injection frequency and side effect tolerance. Patients with diabetes may benefit more from tirzepatide's superior glycaemic control, whilst those prioritising established cardiovascular outcome data may prefer semaglutide.

Clinical experience at Cured Pharmacy shows many patients achieve excellent results with Mounjaro 7.5mg as a maintenance dose, avoiding the need for higher 10mg or 15mg escalation. Others find Wegovy 2.4mg provides optimal appetite control with manageable side effects. The decision should be made collaboratively with a prescriber during the online consultation, considering medical history, current medications, and weight loss goals. Both treatments require commitment to dietary modification and increased physical activity for maximum benefit, as medication alone produces suboptimal outcomes without lifestyle intervention [4].

Scientific References

1. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. [accessed 15 August 2026]
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 15 August 2026]
3. Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Molecular Metabolism, 46, 101102. [accessed 15 August 2026]
4. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.